Bringing Discoveries to Commercialization
ICBI company, Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children’s Hospital Receive a $2.3 Million Dollar Phase II SBIR Grant to Develop Novel Therapy

Events

ICBI company, Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children’s Hospital Receive a $2.3 Million Dollar Phase II SBIR Grant to Develop Novel Therapy

Friday, August 23, 2019

Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that they are a recipient of a Phase II SBIR grant from the National Institutes of Health (NIH) for $2.3 million. The Phase II award is to continue to support the research with Scioto’s collaborator, the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital in Columbus, Ohio. The funding will be used to develop Scioto’s proprietary therapeutic SB-121, which is a unique formulation used to deliver healthy, activated probiotic or beneficial bacteria to the gastrointestinal tract. Scioto’s strategy of delivering healthy bacteria to the GI tract can be used to treat a number of different disorders ranging from infectious diseases to disorders effecting the gut-brain axis, such as autism and depression.